Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Continuing Education

Indium-111 Satumomab Pendetide: The First FDA-Approved Monoclonal Antibody for Tumor Imaging

Paul J. Bohdiewicz
Journal of Nuclear Medicine Technology September 1998, 26 (3) 155-163;
Paul J. Bohdiewicz
Nuclear Medicine Department, William Beaumont Hospital, Royal Oak, Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Objective: Colon cancer is the second most common cause of cancer mortality. Ovarian cancer is the most common gynecologic malignancy cause of death in women.

A labeled monoclonal antibody attaches to a tumor-associated antigen and allows these tumor masses to be imaged or treated, depending on the radionuclide used. Indium-111 satumomab pendetide was the first labeled monoclonal antibody to be approved by the Food and Drug Administration (FDA) for tumor imaging. It is reactive with most colorectal and ovarian cancers, as well as other cancers.

After reading this article, the technologist will understand the FDA approval process, phase trial results, safety and adverse reactions, human antimurine antibody response, indications, imaging protocol, and strengths and weaknesses of imaging with satumomab pendetide. Representative cases are presented.

  • indium-111 satumomab pendetide
  • indium-111 OncoScint® CR-OV
  • monoclonal antibody
  • radionuclide tumor imaging
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 26 (3)
Journal of Nuclear Medicine Technology
Vol. 26, Issue 3
September 1, 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Indium-111 Satumomab Pendetide: The First FDA-Approved Monoclonal Antibody for Tumor Imaging
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Indium-111 Satumomab Pendetide: The First FDA-Approved Monoclonal Antibody for Tumor Imaging
Paul J. Bohdiewicz
Journal of Nuclear Medicine Technology Sep 1998, 26 (3) 155-163;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Indium-111 Satumomab Pendetide: The First FDA-Approved Monoclonal Antibody for Tumor Imaging
Paul J. Bohdiewicz
Journal of Nuclear Medicine Technology Sep 1998, 26 (3) 155-163;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Fifty Years of Radiopharmaceuticals
  • Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors
  • Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer
  • Google Scholar

More in this TOC Section

  • Illuminating the Hidden: Standardizing Cardiac MIBG Imaging for Sympathetic Dysfunction
  • PET/CT Case Series: Unmasking the Mystery of Cardiac Sarcoidosis
  • Delivery Methods of Radiopharmaceuticals: Exploring Global Strategies to Minimize Occupational Radiation Exposure
Show more Continuing Education

Similar Articles

Keywords

  • indium-111 satumomab pendetide
  • indium-111 OncoScint® CR-OV
  • monoclonal antibody
  • radionuclide tumor imaging
SNMMI

© 2025 SNMMI

Powered by HighWire